ROYAL BANK OF CANADA - ATYR PHARMA INC ownership

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of ATYR PHARMA INC
ValueSharesWeighting
Q3 2023$128,000
-29.7%
80,973
-4.1%
0.00%
Q2 2023$182,000
+13.0%
84,429
+9.5%
0.00%
Q1 2023$161,000
+2.5%
77,073
+7.4%
0.00%
Q4 2022$157,000
+6.8%
71,768
+47.3%
0.00%
Q3 2022$147,000
+14600.0%
48,727
+8857.2%
0.00%
Q2 2022$1,000
-85.7%
544
-59.2%
0.00%
Q1 2022$7,000
+75.0%
1,334
+166.8%
0.00%
Q4 2021$4,000500
+49900.0%
0.00%
Q2 2021$010.0%0.00%
Q4 2019$010.00%
Other shareholders
ATYR PHARMA INC shareholders Q4 2023
NameSharesValueWeighting ↓
Tikvah Management LLC 1,225,833$9,157,0002.55%
Stonepine Capital Management, LLC 525,531$3,926,0001.80%
Telemetry Investments, L.L.C. 176,782$1,321,0001.70%
TANG CAPITAL MANAGEMENT LLC 1,113,453$8,317,0001.67%
VR Adviser, LLC 1,565,000$11,691,0001.60%
Deep Track Capital, LP 1,100,000$8,217,0000.58%
EAM Investors, LLC 252,280$1,885,0000.31%
EAM Global Investors LLC 152,792$1,141,0000.20%
FEDERATED HERMES, INC. 5,222,250$39,010,0000.07%
Alyeska Investment Group, L.P. 674,975$5,042,0000.06%
View complete list of ATYR PHARMA INC shareholders